Moreover, the CRC patients with alteration in JAG1 (p = 0.0077) or ACTN2 (p = 0.0233) or MYCN (p = 0.0297) had lower survival rates than the CRC patients with normal JAG1 or ACTN2 or MYCN expression. This evidence concerns the gene MYCN and colorectal carcinoma.